Trial Profile
A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 03 Aug 2009 Results have been reported at the 13th World Conference on Lung Cancer.
- 19 Dec 2006 Status change
- 02 Sep 2005 New trial record.